扶正祛毒方对慢性乙型肝炎病毒携带小鼠细胞免疫水平的调节作用

Abstract
Figure/Table
References (21)
Related Citation (14)

Download: PDF (636 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the regulation of Fuzheng Qudu Decoction on cellular immunity of mice carrying chronic hepatitis B virus (HBV). Methods Thirty male HBV transgenic C57BL/6J mice were selected, and they were randomly divided into the model group, the Western medicine group, and the traditional Chinese medicine group according to the random number table method, with 10 mice in each group, and 10 normal male (non-transgenic) mice of the same line as the blank group. The traditional Chinese medicine group was given Fuzheng Qudu Decoction 0.10 mL/ (10 g·d) by gavage, the Western medicine group was given Adefovir Dipivoxil 0.08 mL/ (10 g·d) by gavage, the model group and the blank group were given physiological saline 0.10 mL/(10 g·d) by gavage, and all groups were administered once every day. After 24 weeks, the mice were sacrificed and taken, and the proportions of CD8+T lymphocytes and CD4+T lymphocytes in the peripheral blood of the mice were detected by flow cytometry, and the CD4+T/CD8+T was calculated. Enzyme-linked immunosorbent assay was used to measure the levels of interleukin (IL)-2 and IL-4 in liver tissue, which indirectly reflected the ratio of Th1 to Th2 in helper T cells (Th). Results The proportion of CD8+T lymphocytes in the traditional Chinese medicine group was higher than that in the model group (P ＜ 0.05). CD4+T/CD8+T in the model group was higher than that in the blank group (P ＜ 0.05). CD4+T/CD8+T in the Western medicine group and the traditional Chinese medicine group were lower than that in the model group (P ＜ 0.05). The level of IL-2 in the model group was higher than that in the blank group (P ＜ 0.05), and the level of IL-2 in the traditional Chinese medicine group was higher than that in the Western medicine group and the model group (P ＜ 0.05). The level of IL-4 in the model group was higher than that in the blank group (P ＜ 0.05), and the level of IL-4 in the the Western medicine group and the traditional Chinese medicine group were lower than that in the model group (P ＜ 0.05). Conclusion Fuzheng Qudu Decoction can improve the cellular immune level of chronic HBV carrying mice, its mechanism may be related to the regulation of the proportion of Th1/Th2.

Key words： Hepatitis B virus Fuzheng Qudu Decoction CD4+T/CD8+T Th1/Th2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Bingran1
	2 ZHANG Liping1
	2 GUO Zining2 PENG Long1
	2

Cite this article:

WANG Bingran1,2 ZHANG Liping1,2 GUO Zining2 PENG Long1, et al. Regulating effect of Fuzheng Qudu Decoction on cellular immunity of mice carrying chronic hepatitis B virus[J]. 中国医药导报, 2020, 17(35): 19-22.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I35/19

[1] Razavi-Shearer D，Gamkrelidze I，Nguyen M H，et al. Global prevalence，treatment，and prevention of hepatitis B virus infection in 2016：a modelling study [J]. Lancet Gastroenterol Hepatol，2018，3（6）：383-403.
[2] Trepo C，Chan HL，Lok A. Hepatitis B virus infection [J]. Lancet，2014，384（9959）：2053-2063.
[3] Wang FS，Fan JG，Zhang Z，et al. The global burden of liver disease：the major impact of China [J]. Hepatology，2014， 60（6）：2099-2108.
[4] Pyrski M，Rugowska A，Wierzbinski KR，et al. HBcAg produced in transgenic tobacco triggers Th1 and Th2 response when intramuscularly delivered [J]. Vaccine，2017， 35（42）：5714-5721.
[5] Liu YM，Xu QY，Chen JX，et al. Investigation on effects of the nourishing kidney and eliminating toxicity decoction on immunological imbalance of Th1，Th17 and Treg in HBV transgenic mice [J]. Int J Clin Exp Med，2015，8（5）：6735-6742.
[6] 袁慧鑫，郭子宁.慢性HBV携带小鼠模型评估[J].福建中医药，2019，50（1）：30-31，35.
[7] 南月敏.中西医结合传染病学[M].北京：中国中医药出版社，2009：40.
[8] 彭龙，张立平，郭子宁，等.扶正祛毒方对慢性乙肝病毒携带小鼠肝组织γ-干扰素和白介素-10表达影响的研究[J].环球中医药，2019，12（6）：835-838.
[9] 蔡洋，钟群燕，连开伟，等.中医药调控免疫治疗自身抗体阳性慢性乙肝的研究[J].中医临床研究，2019，11（3）：66-68.
[10] 朱明清，江云，孙学华，等.补肾健脾法治疗慢性乙型肝炎的理论探讨[J].辽宁中医杂志，2018，45（4）：712-714.
[11] Ichiki Y，He XS，Shimoda S，et al. T cell immunity in hepatitis B and hepatitis C virus infection：implications for autoimmunity [J]. Autoimmun Rev，2005，4（2）：82-95.
[12] 董燕，黄象安，郭子宁.乙型肝炎慢性化机制研究[J].辽宁中医药大学学报，2018，20（6）：67-70.
[13] 刘宁，徐杰，刘金花，等.慢性乙型肝炎、乙肝肝硬化、乙肝肝癌患者Th1/Th2型细胞因子水平变化研究[J].胃肠病学和肝病学杂志，2014，23（2）：158-161.
[14] 谢维丽，王少扬，刘海周，等.肝郁脾虚型慢性乙型肝炎患者Th1/Th2类细胞功能研究[J].医学理论与实践，2018， 31（16）：2386-2388.
[15] 郭子宁，张立平，黄象安，等.基于Th1/Th2细胞因子表达变化探讨扶正祛毒方对慢性HBV携带者的免疫调节机制[J].环球中医药，2018，11（12）：1874-1878.
[16] 王琴.免疫活化/耐受环境转换对乙肝病毒抗原特异性CD8+T细胞功能的影响研究[D].武汉：华中科技大学，2018.
[17] Li WY，Jiang YF，Jin QL，et al. Immunologic characterization of posthepatitis cirrhosis caused by HBV and HCV infection [J]. J Biomed Biotechnol，2010，2010：138237.
[18] Gu YR，Chen LB，Lian YF，et al. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-na?觙ve chronic hepatitis B patients [J]. J Med Virol，2020，92（3）：317-328.
[19] 李铃，古雪，梅怡晗，等.辅助性T细胞亚型与慢性乙型肝炎的关系[J].川北医学院学报，2016，31（4）：618-621.
[20] 刘建兵.中药黄芪的药理作用及临床应用效果观察[J].临床医药文献电子杂志，2019，6（70）：141.
[21] 周凌凌，胡筱希，丁霞.半枝莲提取物抗乙肝病毒体外实验研究[J].中药材，2015，38（5）：1042-1045.